Top

BMC Cancer

Published in:

Open Access 01-12-2010 | Research article

Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues

Authors: Carol D Curtis, Daniel L Thorngren, Ann M Nardulli

Published in: BMC Cancer | Issue 1/2010

Abstract

Background

During the course of normal cellular metabolism, oxygen is consumed and reactive oxygen species (ROS) are produced. If not effectively dissipated, ROS can accumulate and damage resident proteins, lipids, and DNA. Enzymes involved in redox regulation and DNA repair dissipate ROS and repair the resulting damage in order to preserve a functional cellular environment. Because increased ROS accumulation and/or unrepaired DNA damage can lead to initiation and progression of cancer and we had identified a number of oxidative stress and DNA repair proteins that influence estrogen responsiveness of MCF-7 breast cancer cells, it seemed possible that these proteins might be differentially expressed in normal mammary tissue, benign hyperplasia (BH), ductal carcinoma in situ (DCIS) and invasive breast cancer (IBC).

Methods

Immunohistochemistry was used to examine the expression of a number of oxidative stress proteins, DNA repair proteins, and damage markers in 60 human mammary tissues which were classified as BH, DCIS or IBC. The relative mean intensity was determined for each tissue section and ANOVA was used to detect statistical differences in the relative expression of BH, DCIS and IBC compared to normal mammary tissue.

Results

We found that a number of these proteins were overexpressed and that the cellular localization was altered in human breast cancer tissue.

Conclusions

Our studies suggest that oxidative stress and DNA repair proteins not only protect normal cells from the damaging effects of ROS, but may also promote survival of mammary tumor cells.

Available only for authorised users

Wiechmann LKH: The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 2008, 112 (10): 2130-2142. 10.1002/cncr.23430.CrossRefPubMed

Jacobs TW, Connolly JL, Schnitt SJ: Nonmalignant lesions in breast core needle biopsies: to excise or not to excise?. Am J Surg Pathol. 2002, 26 (9): 1095-1110. 10.1097/00000478-200209000-00001.CrossRefPubMed

Horak CE, Steeg PS: Metastasis gets site specific. Cancer Cell. 2005, 8 (2): 93-95. 10.1016/j.ccr.2005.07.013.CrossRefPubMed

Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006, 12 (8): 895-904. 10.1038/nm1469.CrossRefPubMed

Harman D: Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956, 11 (3): 298-300.CrossRefPubMed

Fridovich I: Fundamental aspects of reactive oxygen species, or what's the matter with oxygen?. Ann N Y Acad Sci. 1999, 893: 13-18. 10.1111/j.1749-6632.1999.tb07814.x.CrossRefPubMed

Harman D: Aging: overview. Ann N Y Acad Sci. 2001, 928: 1-21.CrossRefPubMed

Muller FL, Lustgarten MS, Jang Y, Richardson A, Van Remmen H: Trends in oxidative aging theories. Free Radic Biol Med. 2007, 43 (4): 477-503. 10.1016/j.freeradbiomed.2007.03.034.CrossRefPubMed

Benz CC, Yau C: Ageing, oxidative stress and cancer: paradigms in parallax. Nat Rev Cancer. 2008, 8 (11): 875-879. 10.1038/nrc2522.CrossRefPubMedPubMedCentral

10.

Zelko IN, Mariani TJ, Folz RJ: Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med. 2002, 33 (3): 337-349. 10.1016/S0891-5849(02)00905-X.CrossRefPubMed

11.

Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996, 271 (5 Pt 1): C1424-1437.PubMed

12.

Whittal RM, Benz CC, Scott G, Semyonov J, Burlingame AL, Baldwin MA: Preferential oxidation of zinc finger 2 in estrogen receptor DNA-binding domain prevents dimerization and, hence, DNA binding. Biochemistry. 2000, 39 (29): 8406-8417. 10.1021/bi000282f.CrossRefPubMed

13.

Webster KA, Prentice H, Bishopric NH: Oxidation of zinc finger transcription factors: physiological consequences. Antioxid Redox Signal. 2001, 3 (4): 535-548. 10.1089/15230860152542916.CrossRefPubMed

14.

Evans AR, Limp-Foster M, Kelley MR: Going APE over ref-1. Mutat Res. 2000, 461 (2): 83-108.CrossRefPubMed

15.

Schultz-Norton JR, McDonald WH, Yates JR, Nardulli AM: Protein disulfide isomerase serves as a molecular chaperone to maintain estrogen receptor α structure and function. Mol Endocrinol. 2006, 20 (9): 1982-1995. 10.1210/me.2006-0006.CrossRefPubMed

16.

Rao AK, Ziegler YS, McLeod IX, Yates JR, Nardulli AM: Effects of Cu/Zn superoxide dismutase on estrogen responsiveness and oxidative stress in human breast cancer cells. Mol Endocrinol. 2008, 22 (5): 1113-1124. 10.1210/me.2007-0381.CrossRefPubMedPubMedCentral

17.

Rao AK, Ziegler YS, McLeod IX, Yates JR, Nardulli AM: Thioredoxin and thioredoxin reductase influence estrogen receptor {alpha} mediated gene expression in human breast cancer cells. J Mol Endocrinol. 2009, 43 (6): 251-261. 10.1677/JME-09-0053.CrossRefPubMedPubMedCentral

18.

Curtis CD, Thorngren DL, Ziegler YS, Sarkeshik A, Yates JR, Nardulli AM: Apurinic/apyrimidinic endonuclease 1 alters estrogen receptor activity and estrogen responsive gene expression. Mol Endocrinol. 2009, 23 (9): 1346-1360. 10.1210/me.2009-0093.CrossRefPubMedPubMedCentral

19.

Demple B, Sung JS: Molecular and biological roles of Ape1 protein in mammalian base excision repair. DNA Repair. 2005, 4 (12): 1442-1449. 10.1016/j.dnarep.2005.09.004.CrossRefPubMed

20.

Sweasy JB, Lang T, DiMaio D: Is base excision repair a tumor suppressor mechanism?. Cell Cycle. 2006, 5 (3): 250-259.CrossRefPubMed

21.

Coquerelle T, Dosch J, Kaina B: Overexpression of N-methylpurine-DNA glycosylase in Chinese hamster ovary cells renders them more sensitive to the production of chromosomal aberrations by methylating agents: a case of imbalanced DNA repair. Mutat Res. 1995, 336: 9-17.CrossRefPubMed

22.

Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998, 273 (10): 5858-5868. 10.1074/jbc.273.10.5858.CrossRefPubMed

23.

Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM: A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol. 2000, 10 (15): 886-895. 10.1016/S0960-9822(00)00610-2.CrossRefPubMed

24.

Bertram JS: The molecular biology of cancer. Mol Aspects Med. 2000, 21 (6): 167-223. 10.1016/S0098-2997(00)00007-8.CrossRefPubMed

25.

Likhite VS, Cass EI, Anderson SD, Yates JR, Nardulli AM: Interaction of estrogen receptor alpha with 3-methyladenine DNA glycosylase modulates transcription and DNA repair. J Biol Chem. 2004, 279 (16): 16875-16882. 10.1074/jbc.M313155200.CrossRefPubMed

26.

Curtis CD, Likhite VS, McLeod IX, Yates JR, Nardulli AM: Interaction of the tumor metastasis suppressor nonmetastatic protein 23 homologue H1 and estrogen receptor alpha alters estrogen-responsive gene expression. Cancer Res. 2007, 67 (21): 10600-10607. 10.1158/0008-5472.CAN-07-0055.CrossRefPubMed

27.

Hartsough MT, Steeg PS: Nm23/nucleoside diphosphate kinase in human cancers. J Bioenerg Biomembr. 2000, 32 (3): 301-308. 10.1023/A:1005597231776.CrossRefPubMed

28.

Bertheau P, Steinberg SM, Merino MJ: C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol. 1998, 29 (4): 323-329. 10.1016/S0046-8177(98)90111-3.CrossRefPubMed

29.

Duenas-Gonzalez A, Abad-Hernandez MM, Garcia-Mata J, Paz-Bouza JI, Cruz-Hernandez JJ, Gonzalez-Sarmiento R: Analysis of nm23-H1 expression in breast cancer. Correlation with p53 expression and clinicopathologic findings. Cancer Lett. 1996, 101 (2): 137-142. 10.1016/0304-3835(96)04131-6.CrossRefPubMed

30.

Yoshida H, Kijima H, Terasaki Y, Suto A, Takeshita T, Omiya H, Shimojima K, Shimbori M, Sato T, Sato S, et al: Heterogeneous expression of nm23 gene product as a predictor of lymph nodal status in human breast cancer. Int J Oncol. 1998, 13 (6): 1141-1146.PubMed

31.

Schultz-Norton JR, Ziegler YS, Likhite VS, Nardulli AM: Isolation of proteins associated with the DNA-bound estrogen receptor α. Molecular Endocrinology: A Comprehensive Guide to Current Methodologies. Edited by: Park Sarge O-K, Curry T. 2009, Totowa, NJ: Humana Press, USA, 590: 209-221.CrossRef

32.

Schultz-Norton JR, Ziegler YS, Likhite VS, Yates JR, Nardulli AM: Isolation of novel coregulatory protein networks associated with DNA-bound estrogen receptor alpha. BMC Mol Biol. 2008, 9: 97-10.1186/1471-2199-9-97.CrossRefPubMedPubMedCentral

33.

Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J: AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA. 1997, 94 (8): 3633-3638. 10.1073/pnas.94.8.3633.CrossRefPubMedPubMedCentral

34.

Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, Prives C: Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 1997, 11 (5): 558-570. 10.1101/gad.11.5.558.CrossRefPubMed

35.

Grzenkowicz-Wydra J, Cisowski J, Nakonieczna J, Zarebski A, Udilova N, Nohl H, Jozkowicz A, Podhajska A, Dulak J: Gene transfer of CuZn superoxide dismutase enhances the synthesis of vascular endothelial growth factor. Mol Cell Biochem. 2004, 264 (1-2): 169-181. 10.1023/B:MCBI.0000044386.45054.70.CrossRefPubMed

36.

Juarez JC, Betancourt O, Pirie-Shepherd SR, Guan X, Price ML, Shaw DE, Mazar AP, Donate F: Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006, 12 (16): 4974-4982. 10.1158/1078-0432.CCR-06-0171.CrossRefPubMed

37.

Mustacich D, Powis G: Thioredoxin reductase. Biochem J. 2000, 346 (Pt 1): 1-8. 10.1042/0264-6021:3460001.CrossRefPubMedPubMedCentral

38.

Bobola MS, Blank A, Berger MS, Stevens BA, Silber JR: Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res. 2001, 7 (11): 3510-3518.PubMed

39.

Kelley MR, Cheng L, Foster R, Tritt R, Jiang J, Broshears J, Koch M: Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res. 2001, 7 (4): 824-830.PubMed

40.

Robertson KA, Bullock HA, Xu Y, Tritt R, Zimmerman E, Ulbright TM, Foster RS, Einhorn LH, Kelley MR: Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res. 2001, 61 (5): 2220-2225.PubMed

41.

Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD: Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 2002, 62 (10): 2890-2896.PubMed

42.

Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM: The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 2003, 23 (3B): 2425-2433.PubMed

43.

Turunen N, Karihtala P, Mantyniemi A, Sormunen R, Holmgren A, Kinnula VL, Soini Y: Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma. Apmis. 2004, 112 (2): 123-132. 10.1111/j.1600-0463.2004.apm1120207.x.CrossRefPubMed

44.

Powis G, Mustacich D, Coon A: The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med. 2000, 29 (3-4): 312-322. 10.1016/S0891-5849(00)00313-0.CrossRefPubMed

45.

Welsh SJ, Bellamy WT, Briehl MM, Powis G: The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002, 62 (17): 5089-5095.PubMed

46.

Smart DK, Ortiz KL, Mattson D, Bradbury CM, Bisht KS, Sieck LK, Brechbiel MW, Gius D: Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res. 2004, 64 (18): 6716-6724. 10.1158/0008-5472.CAN-03-3990.CrossRefPubMed

47.

Burke-Gaffney A, Callister ME, Nakamura H: Thioredoxin: friend or foe in human disease?. Trends Pharmacol Sci. 2005, 26 (8): 398-404. 10.1016/j.tips.2005.06.005.CrossRefPubMed

48.

Zou GM, Luo MH, Reed A, Kelley MR, Yoder MC: Ape1 regulates hematopoietic differentiation of embryonic stem cells through its redox functional domain. Blood. 2007, 109 (5): 1917-1922. 10.1182/blood-2006-08-044172.CrossRefPubMed

49.

Fishel ML, Kelley MR: The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med. 2007, 28 (3-4): 375-395. 10.1016/j.mam.2007.04.005.CrossRefPubMed

50.

Mukherjee A, Martin SG: The thioredoxin system: a key target in tumour and endothelial cells. Br J Radiol. 2008, 81 (Spec No 1): S57-68. 10.1259/bjr/34180435.CrossRefPubMed

51.

Goplen D, Wang J, Enger PO, Tysnes BB, Terzis AJ, Laerum OD, Bjerkvig R: Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. 2006, 66 (20): 9895-9902. 10.1158/0008-5472.CAN-05-4589.CrossRefPubMed

52.

Hansen WK, Kelley MR: Review of mammalian DNA repair and translational implications. J Pharmacol Exp Ther. 2000, 295 (1): 1-9.PubMed

53.

Scharer OD, Jiricny J: Recent progress in the biology, chemistry and structural biology of DNA glycosylases. Bioessays. 2001, 23: 270-281. 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J.CrossRefPubMed

54.

Fishel ML, Seo YR, Smith ML, Kelley MR: Imbalancing the DNA base excision repair pathway in the mitochondria; targeting and overexpressing N-methylpurine DNA glycosylase in mitochondria leads to enhanced cell killing. Cancer Res. 2003, 63 (3): 608-615.PubMed

55.

Rinne M, Caldwell D, Kelley MR: Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. Mol Cancer Ther. 2004, 3 (8): 955-967.PubMed

56.

Engelward BP, Allan JM, Dreslin AJ, Kelly JD, Wu MM, Gold B, Samson LD: A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. J Biol Chem. 1998, 273: 5412-5418. 10.1074/jbc.273.9.5412.CrossRefPubMed

57.

Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J: Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003, 112 (5): 659-672. 10.1016/S0092-8674(03)00150-8.CrossRefPubMed

58.

Chowdhury D, Beresford PJ, Zhu P, Zhang D, Sung JS, Demple B, Perrino FW, Lieberman J: The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol Cell. 2006, 23 (1): 133-142. 10.1016/j.molcel.2006.06.005.CrossRefPubMed

59.

Steeg PS: Search for metastasis suppressor genes. Invasion Metastasis. 1989, 9 (6): 351-359.PubMed

60.

Steeg PS, Palmieri D, Ouatas T, Salerno M: Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer. Cancer Lett. 2003, 190 (1): 1-12. 10.1016/S0304-3835(02)00499-8.CrossRefPubMed

61.

Steeg PS, Ouatas T, Halverson D, Palmieri D, Salerno M: Metastasis suppressor genes: basic biology and potential clinical use. Clin Breast Cancer. 2003, 4 (1): 51-62. 10.3816/CBC.2003.n.012.CrossRefPubMed

62.

Heimann R, Ferguson DJ, Hellman S: The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer. Cancer Res. 1998, 58 (13): 2766-2771.PubMed

63.

Leone A, Flatow U, VanHoutte K, Steeg PS: Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene. 1993, 8 (9): 2325-2333.PubMed

64.

Russell RL, Pedersen AN, Kantor J, Geisinger K, Long R, Zbieranski N, Townsend A, Shelton B, Brunner N, Kute TE: Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. Br J Cancer. 1998, 78 (6): 710-717.CrossRefPubMedPubMedCentral

65.

Li Z, Xiang J, Zhang W, Fan S, Wu M, Li X, Li G: Nanoparticle delivery of anti-metastatic NM23-H1 gene improves chemotherapy in a mouse tumor model. Cancer Gene Ther. 2009, 16 (5): 423-429. 10.1038/cgt.2008.97.CrossRefPubMed

66.

Malins DC, Haimanot R: Major alterations in the nucleotide structure of DNA in cancer of the female breast. Cancer Res. 1991, 51 (19): 5430-5432.PubMed

67.

Toyokuni S, Okamoto K, Yodoi J, Hiai H: Persistent oxidative stress in cancer. FEBS Lett. 1995, 358 (1): 1-3. 10.1016/0014-5793(94)01368-B.CrossRefPubMed

68.

Malins DC, Anderson KM, Jaruga P, Ramsey CR, Gilman NK, Green VM, Rostad SW, Emerman JT, Dizdaroglu M: Oxidative changes in the DNA of stroma and epithelium from the female breast: potential implications for breast cancer. Cell Cycle. 2006, 5 (15): 1629-1632.CrossRefPubMed

69.

Beckman JS, Carson M, Smith CD, Koppenol WH: ALS, SOD and peroxynitrite. Nature. 1993, 364 (6438): 584-10.1038/364584a0.CrossRefPubMed

70.

Squadrito GL, Pryor WA: Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic Biol Med. 1998, 25 (4-5): 392-403. 10.1016/S0891-5849(98)00095-1.CrossRefPubMed

71.

Bianchi MS, Bianchi NO, Bolzan AD: Superoxide dismutase activity and superoxide dismutase-1 gene methylation in normal and tumoral human breast tissues. Cancer Genet Cytogenet. 1992, 59 (1): 26-29. 10.1016/0165-4608(92)90152-X.CrossRefPubMed

72.

Starcevic SL, Diotte NM, Zukowski KL, Cameron MJ, Novak RF: Oxidative DNA damage and repair in a cell lineage model of human proliferative breast disease (PBD). Toxicol Sci. 2003, 75 (1): 74-81. 10.1093/toxsci/kfg154.CrossRefPubMed

73.

Wang D, Luo M, Kelley MR: Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther. 2004, 3 (6): 679-686.PubMed

74.

McNeill DR, Wilson DM: A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol Cancer Res. 2007, 5 (1): 61-70. 10.1158/1541-7786.MCR-06-0329.CrossRefPubMed

75.

Brown DP, Chin-Sinex H, Nie B, Mendonca MS, Wang M: Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer. Cancer Chemother Pharmacol. 2009, 63 (4): 723-730. 10.1007/s00280-008-0791-x.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/9/prepub

Title: Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues
Authors: Carol D Curtis
Daniel L Thorngren
Ann M Nardulli
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-10-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer

Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models

Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone

Dysregulated miR-183 inhibits migration in breast cancer cells

Identification of viral infections in the prostate and evaluation of their association with cancer

Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer